| abstract |
The present disclosure provides compositions, methods of manufacture, and methods of use of antibodies and fragments that bind S. aureus alpha toxin. More specifically, the present disclosure provides the VH CDR and VL CDR region sequences of antibodies or antigen-binding fragments. Also disclosed are methods of preventing, treating or managing conditions associated with S. aureus infection. |